FARZAD SHOKRI-TABIBZADEH: Open Payments
NPI 1801819180 · PORT WASHINGTON, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,158 in 49 payments from 13 companies in 2025. Trend: 2023 $1,265 · 2024 $1,374 · 2025 $1,158
Food & beverage: $1,158
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $213 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $201 |
| AstraZeneca Pharmaceuticals LP | 7 | $147 |
| Eisai Inc. | 1 | $125 |
| Sumitomo Pharma America, Inc. | 4 | $104 |
| Amgen Inc. | 4 | $100 |
| Lilly USA, LLC | 3 | $64 |
| ABBVIE INC. | 3 | $57 |
| Novartis Pharmaceuticals Corporation | 2 | $55 |
| Lundbeck LLC | 1 | $26 |
Products named: CAPLYTA, XIFAXAN, FARXIGA, Leqembi, GEMTESA, OTEZLA, JARDIANCE, VRAYLAR.
Industry payments across NY — which companies pay providers there.
